Recent studies using
glycogen synthase kinase-3beta (GSK-3beta)-deficient mouse embryonic fibroblasts suggest that
GSK-3beta positively regulates
nuclear factor kappaB (NFkappaB)-mediated gene transcription. Because NFkappaB is suggested to participate in cell proliferation and survival pathways in
pancreatic cancer, we investigated the role of
GSK-3beta in regulating these cellular processes. Herein, we show that
pancreatic cancer cells contain a pool of active
GSK-3beta and that pharmacologic inhibition of
GSK-3 kinase activity using small molecule inhibitors or genetic depletion of
GSK-3beta by RNA interference leads to decreased
cancer cell proliferation and survival. Mechanistically, we show that
GSK-3beta influences NFkappaB-mediated gene transcription at a point distal to the Ikappa
kinase complex, as only ectopic expression of the NFkappaB subunits p65/p50, but not an Ikappa
kinase beta constitutively active mutant, could rescue the decreased cellular proliferation and survival associated with
GSK-3beta inhibition. Taken together, our results simultaneously identify a previously unrecognized role for
GSK-3beta in
cancer cell survival and proliferation and suggest
GSK-3beta as a potential therapeutic target in the treatment of
pancreatic cancer.